Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020

July 2020 | 65 pages | ID: V6FDB9BA5E06EN
Global Markets Direct

Abstracts

Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020

SUMMARY

According to the recently published report 'Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020'; Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) pipeline Target constitutes close to 16 molecules.
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Vascular endothelial growth factor B also known as VEGF-B is a protein encoded by the VEGF-B gene. It regulates the formation of blood vessels and is involved in endothelial cell physiology. It is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1).
The report 'Vascular Endothelial Growth Factor B - Pipeline Review, H2 2020' outlays comprehensive information on the Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 5, 6, 3 and 2 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Wet (Neovascular/Exudative) Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Choroidal Neovascularization, Diabetic Nephropathy, Lipid Disorders, Metastatic Colorectal Cancer, Non-Proliferative Diabetic Retinopathy (NPDR) and Uveal Melanoma.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
• The report reviews Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics and enlists all their major and minor projects
• The report assesses Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Overview
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Companies Involved in Therapeutics Development
Alteogen Inc
Amgen Inc
Cinnagen Co
Clover Biopharmaceuticals
Coherus BioSciences Inc
CSL Ltd
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Sam Chun Dang Pharm Co Ltd
Samsung Bioepis Co Ltd
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Dormant Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Discontinued Products
Vascular Endothelial Growth Factor B (VEGF Related Factor or VEGFB) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Alteogen Inc, H2 2020
Pipeline by Amgen Inc, H2 2020
Pipeline by Cinnagen Co, H2 2020
Pipeline by Clover Biopharmaceuticals, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Alteogen Inc
Amgen Inc
Cinnagen Co
Clover Biopharmaceuticals
Coherus BioSciences Inc
CSL Ltd
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Sam Chun Dang Pharm Co Ltd
Samsung Bioepis Co Ltd